Lantern Pharma (LTRN) announced that the European Patent Office has issued a notice of allowance for a composition of matter patent covering its drug candidate LP-284. This patent is expected to be granted in the coming months with exclusivity through early 2039.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LTRN: